Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 112
- Registration Number
- NCT00621049
- Locations
- 🇺🇸
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
🇺🇸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00613145
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00611689
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-02-11
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00611793
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 53
- Registration Number
- NCT00609804
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 166
- Registration Number
- NCT00600015
- Locations
- 🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus, Ohio, United States
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT00594230
- Locations
- 🇺🇸
Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States
🇺🇸Northeast Georgia Medical Center, Gainesville, Georgia, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
RAD001 Plus Bevacizumab in Metastatic Melanoma
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00591734
- Locations
- 🇺🇸
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
🇺🇸Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Florida Hospital Cancer Institute, Orlando, Florida, United States
LBH589, Paclitaxel, Carboplatin +/- Bevacizumab for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2007-11-09
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00556088
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
LBH589 and Gemcitabine in the Treatment of Solid Tumors
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2013-08-19
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00550199
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States